OBJECTIVES: To describe the incidence of thrombotic complications across all 3 stages of single ventricle palliation and the association between thromboprophylaxis use and thrombotic risk. STUDY DESIGN: Two separate cross-sectional studies were performed that included 195 patients born between 2003-2008 and 162 patients who underwent Fontan after 2000. RESULTS: The incidence of thrombotic complications was 40% and 28% after initial palliation and superior cavopulmonary connection (SCPC), respectively; 5-year freedom from thrombotic complications after Fontan was 79%. Thromboprophylaxis was initiated for 70%, 46%, and 94% of patients after initial palliation, SCPC, and Fontan, respectively. Thromboprophylaxis with enoxaparin (vs no thromboprophylaxis) was associated with a reduction in risk of thrombotic complications after initial palliation (hazard ratio [HR] 0.5, P = .05) and SCPC (HR 0.2, P = .04). Thromboprophylaxis with warfarin was associated with a reduction in thrombotic complications after Fontan (HR 0.27, P = .05 vs acetylsalicylic acid; HR 0.18, P = .02 vs no thromboprophylaxis). Thrombotic complications were associated with increased mortality after initial palliation (HR 5.5, P < .001) and SCPC (HR 12.5, P < .001). Three patients experienced major bleeding complications without permanent sequelae (2 enoxaparin, 1 warfarin). CONCLUSIONS: Given the negative impact of thrombotic complications on survival, the low risk of serious bleeding complications, and the association between thromboprophylaxis and lowered thrombotic complication risk across all 3 palliative stages, routine use of thromboprophylaxis from the initial palliation to the early post-Fontan period in this population may be indicated.
OBJECTIVES: To describe the incidence of thrombotic complications across all 3 stages of single ventricle palliation and the association between thromboprophylaxis use and thrombotic risk. STUDY DESIGN: Two separate cross-sectional studies were performed that included 195 patients born between 2003-2008 and 162 patients who underwent Fontan after 2000. RESULTS: The incidence of thrombotic complications was 40% and 28% after initial palliation and superior cavopulmonary connection (SCPC), respectively; 5-year freedom from thrombotic complications after Fontan was 79%. Thromboprophylaxis was initiated for 70%, 46%, and 94% of patients after initial palliation, SCPC, and Fontan, respectively. Thromboprophylaxis with enoxaparin (vs no thromboprophylaxis) was associated with a reduction in risk of thrombotic complications after initial palliation (hazard ratio [HR] 0.5, P = .05) and SCPC (HR 0.2, P = .04). Thromboprophylaxis with warfarin was associated with a reduction in thrombotic complications after Fontan (HR 0.27, P = .05 vs acetylsalicylic acid; HR 0.18, P = .02 vs no thromboprophylaxis). Thrombotic complications were associated with increased mortality after initial palliation (HR 5.5, P < .001) and SCPC (HR 12.5, P < .001). Three patients experienced major bleeding complications without permanent sequelae (2 enoxaparin, 1 warfarin). CONCLUSIONS: Given the negative impact of thrombotic complications on survival, the low risk of serious bleeding complications, and the association between thromboprophylaxis and lowered thrombotic complication risk across all 3 palliative stages, routine use of thromboprophylaxis from the initial palliation to the early post-Fontan period in this population may be indicated.
Authors: Adriane J Sinclair; Christine K Fox; Rebecca N Ichord; Christopher S Almond; Timothy J Bernard; Lauren A Beslow; Anthony K C Chan; Michael Cheung; Gabrielle deVeber; Michael M Dowling; Neil Friedman; Therese M Giglia; Kristin P Guilliams; Tilman Humpl; Daniel J Licht; Mark T Mackay; Lori C Jordan Journal: Pediatr Neurol Date: 2014-10-05 Impact factor: 3.372
Authors: Christoph Sinning; Elvin Zengin; Gerhard Diller; Paulus Kirchhof; Stefan Blankenberg; Carsten Rickers; Yskert von Kodolitsch Journal: Cardiovasc Diagn Ther Date: 2021-12
Authors: Alexander A Boucher; Julia A Heneghan; Subin Jang; Kaitlyn A Spillane; Aaron M Abarbanell; Marie E Steiner; Andrew D Meyer Journal: Front Surg Date: 2022-06-14
Authors: R Mark Payne; Kristin M Burns; Andrew C Glatz; Danshi Li; Xiaodong Li; Paul Monagle; Jane W Newburger; Elizabeth A Swan; Olivia Wheaton; Christoph Male Journal: Am Heart J Date: 2019-08-09 Impact factor: 4.749
Authors: E Vincent S Faustino; Leslie J Raffini; Sheila J Hanson; Jill M Cholette; Matthew G Pinto; Simon Li; Sarah B Kandil; Marianne E Nellis; Veronika Shabanova; Cicero T Silva; Joana A Tala; Tara McPartland; Philip C Spinella Journal: Crit Care Med Date: 2021-04-01 Impact factor: 9.296